New biologic offers hope as first-line colorectal cancer agent
The FDA recently approved bevacizumab (Avastin, Genentech) for use in combination with intravenous 5-fluorouracil-based chemotherapy for the first-line treatment of metastatic CRC. Bevacizumab is the first angiogenesis inhibitor to be approved for use in the U.S. Genentech began to ship bevacizumab to wholesalers within 3 days of its approval.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Related Content
